Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2022

Equity [Abstract]

Share-Based Compensation Expense

Stock-based compensation expense recognized during the three and six months ended June 30, 2022 and 2021 is included in our consolidated statements of operations as shown in the below table. Stock-based compensation expense includes both non-cash expense related to grants of stock-based awards as well as cash expense related to the employee discount applied to purchases of our common stock under our employee stock purchase plan. No stock-based compensation costs were capitalized during the three and six months ended June 30, 2022 and 2021.

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2022		2021		2022		2021
Cost of revenue:
Provider	$	221	$	220	$	538	$	496
Payer & Life Sciences		37		49		25		106
Total cost of revenue		258		269		563		602
Selling, general and administrative expenses		8,309		2,335		13,798		4,888
Research and development		596		938		1,726		2,006
Total stock-based compensation expense	$	9,163	$	3,542	$	16,087	$	7,496

Share-Based Awards Granted

We granted stock-based awards as follows:

	Three Months Ended June 30, 2022				Six Months Ended June 30, 2022
			Weighted-Average				Weighted-Average
			Grant Date				Grant Date
(In thousands, except per share amounts)	Shares		Fair Value		Shares		Fair Value
Service-based restricted stock units		1,221	$	18.41		1,246	$	18.44
Performance-based restricted stock units with a service condition		243	$	18.56		243	$	18.56
Market-based restricted stock units with a service condition		258	$	21.90		258	$	21.90
		1,722	$	18.95		1,747	$	18.97